COVID-19: U.S. Public Health Data and Reporting

Updated June 4, 2020

The daily updated counts of cases and deaths during the COVID-19 pandemic have served as important indicators throughout the crisis—informing policy decisions, research, and public awareness. Ongoing data collection, or surveillance, is a key component of public health practice. As the nation’s lead public health agency, the Centers for Disease Control and Prevention (CDC) has sought to conduct surveillance within the U.S. system of federalism where many public health authorities are based in state law. Some observers have called for improved public health surveillance during the pandemic; this Insight provides an overview of the current systems and policy considerations for Congress.

Overview of U.S. Public Health Surveillance

In the United States, national public health surveillance is conducted through multiple multifaceted systems generally involving the federal, state, territorial, and local (jurisdictional) governments. Much of the original data, such as on COVID-19 virus test results and hospitalizations, are collected from disparate and often private organizations such as laboratories, hospitals, and outpatient health care facilities. Jurisdictions can mandate the collection of certain data from private entities in jurisdictional law and can implement reporting systems. These data are then used to inform jurisdiction-level public health policy and actions. De-identified data are then usually provided voluntarily to CDC by the jurisdictions. CDC provides funding, sets data standards, and provides technical assistance to jurisdictions for surveillance systems. CDC may also conduct national-level public health surveillance by other means, such as through surveys or data collected directly from health care entities or other designated sites.

Current COVID-19 Public Health Surveillance Systems

Throughout the COVID-19 epidemic, some have critiqued the adequacy of U.S. public health surveillance. Aside from data issues related to diagnostic testing, some have critiqued the timeliness of reporting, the availability of additional demographic information on COVID-19 cases (such as on race/ethnicity), and the completeness of COVID-19 mortality data. These critiques point to some long-standing issues with U.S. public health surveillance, including differences in jurisdictional laws and
systems for surveillance, such as for electronic reporting systems and requirements for the medical certification of deaths.

In the current COVID-19 pandemic, CDC and other federal agencies (such as the Federal Emergency Management Agency, FEMA) are collecting many types of data to inform the federal response and to better understand the disease and affected populations. The Department of Health and Human Services (HHS) reportedly consolidates data internally from various sources to inform federal response.

CDC publishes a weekly surveillance report, COVIDView, with data related to COVID-19 outpatient visits, emergency department visits, hospitalizations, deaths, and laboratory data. These data draw upon multiple surveillance systems, including additions to the existing influenza surveillance systems, and mortality data collected through the National Vital Statistics System. These high-level data are intended as indicators for monitoring the pandemic.

CDC also collects more detailed data on COVID-19 cases through the National Notifiable Diseases Surveillance System (NNDSS). In this system, jurisdictions mandate the reporting of certain notifiable diseases from health care entities to jurisdictional health departments, and then voluntarily share de-identified data with CDC. A notifiable disease or condition is one for which “regular, frequent, and timely information regarding individual cases is considered necessary for the prevention and control of the disease or condition.” CDC, with the Council of State and Territorial Epidemiologists, publishes a list of diseases and conditions recommended to be reported by jurisdictions and supports electronic reporting systems. COVID-19 is a reportable disease in all jurisdictions, and CDC has developed a case reporting system. Jurisdictions can report preliminary data through the system and complete records over time as more information is gathered and the patient situation changes.

CDC has published some preliminary research using case report data, including a report on severe outcomes among patients (February 12-March 16, 2020) and on underlying health conditions (February 12-March 28, 2020). These reports note how reporting from jurisdictions can be preliminary and often lacks details on cases. For example, the report on underlying health conditions stated,

the analysis was limited by missing data related to the health department reporting burden associated with rapidly rising case counts and delays in completion of information requiring medical chart review; these findings might change as additional data become available.

Given limitations with NNDSS, CDC also operates COVID-NET, a surveillance system that collects detailed data on COVID-19 hospitalizations in 100 counties across the United States. Data from this system can allow for more robust analyses on subsets of COVID-19 cases, such as published in a CDC report.

Executive Actions and HHS Data Collection

The White House and the HHS Secretary have also taken several actions to request data from several stakeholders, including laboratories, health care providers, and nursing homes. Vice President Michael Pence sent a letter on March 29 to hospital and academic laboratories requesting that data on laboratory results and patient capacity be sent daily to HHS, in addition to any jurisdictions that require reporting. Subsequently, on April 10, HHS Secretary Alex Azar sent a letter to hospital administrators requesting daily COVID-19 data to be submitted to HHS, in addition to any jurisdictions that require reporting. The letter gives hospitals various options to meet these reporting requests, including through a module in CDC’s National Healthcare Safety Network and to a new portal established by an HHS vendor, TeleTracking. According to statements by the American Hospital Association (AHA), TeleTracking data have been used for targeted distributions of the CARES Act Provider Relief Fund and allocations of Remdesivir, the antiviral drug available under a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). Data from TeleTracking do not appear to be included in CDC’s online surveillance summaries.
Congressional Actions

Congress has taken several actions related to public health data and reporting. Section 18115 of the CARES Act (P.L. 116-136) requires laboratories to report COVID-19 test results to the HHS Secretary, as specified. This section repeals a provision related to laboratory reporting in the Families First Coronavirus Response Act (P.L. 116-127, Section 1702). Congress has also appropriated funding in several coronavirus supplemental appropriations acts for grants/cooperative agreements between CDC and jurisdictions for public health functions, including surveillance—not less than $950 million in the first supplemental (P.L. 116-123), not less than $1.5 billion in the CARES Act (P.L. 116-136), and not less than $11 billion in the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA; P.L. 116-139). In addition, the CARES Act includes $500 million to the CDC for “public health data surveillance and analytics infrastructure modernization.” Additional funding for CDC and transfers from other HHS accounts in these acts could also be used by the agency for surveillance purposes.

PPPHCEA also includes several provisions in Division B that require HHS reporting and analysis of data on COVID-19 cases, hospitalizations, and deaths, including two required COVID-19 reports “disaggregated nationally by race, ethnicity, age, sex, geographic region, and other relevant factors.” One of these reports (for which the deadline has passed) has been made available publicly on the Senate Health, Education, Labor, and Pensions (HELP) Committee website.

Policy Considerations

As the COVID-19 pandemic progresses, more comprehensive, location-specific, and timelier data could help support the nation’s continued response, as well as local-level public health decisionmaking, such as informing social distancing guidelines. At the same time, differences in policies and capabilities across jurisdictions may not enable rapid and standardized data collection from the jurisdictions. Surges in cases can also affect reporting capacity. CDC reports that it is working with each jurisdiction to enable complete and timely reporting systems for COVID-19 data that will be adaptable for future health issues. Reporting burden on health care providers may also be an issue—AHA has expressed concern about “federal data requests duplicating those of states and other non-federal entities.” Congress may consider how to optimize federal and jurisdictional reporting to meet various objectives of public health surveillance, including informing emergency response decisionmaking and a better understanding of the disease and affected populations.

Author Information

Kavya Sekar
Analyst in Health Policy

Disclaimer
This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.